Is a complete IKT research report available?

No complete published report is available for Inhibikase Therapeutics, Inc. (IKT) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · USD

$2.33

+0.00 (0.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IKT analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	397.1M
Net income (ttm)	-51M
EPS (ttm)	-$0.43
Shares out	170.4M
Volume	2,158,411
Beta	0.94
Price target	$6.00	+157.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -51M
EPS (ttm): -$0.43
Market cap: 397.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IKT indicators

Market & fundamental data

Available fields

186

Groups with data

Currency

USD

Showing 186 of 186 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001750149
Company name	Inhibikase Therapeutics, Inc.
Country	United States
Country code	US
Cusip	45719W205
Employees	35
Employees Change	19%
Employees Change Percent	118.8
Enterprise value	$226.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-12-23
Isin	US45719W2052
Last refreshed	2026-07-25
Market cap	$397.1M
Market cap category	Small-Cap
Price	$2.33
Price currency	USD
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.64
Sic	2836
Symbol	IKT
Website	https://www.inhibikase.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-12.83%
EV Sales Forward	906.86x
FCF yield	-9%
P/B ratio	2.37x
PS Forward	1,588.34x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-51M
Net Income Growth Years	0%
Profit Per Employee	$-1.5M
ROA	-22.61
Roa5y	-36.33
ROCE	-32.94
ROE	-40.23
Roe5y	-65.8
ROIC	-23.87

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	17.69%
Cagr3y	-5.14%
Cagr5y	-30.76%
EPS Growth Quarters	1
EPS Growth Years	4
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$173.3M
Cash	$170.4M
Current Assets	$172.2M
Current Liabilities	$5.7M
Debt	$0
Equity	$167.6M
Liabilities	$5.7M
Long Term Assets	$1.2M
Long Term Liabilities	$0
Net Cash	$170.4M
Net Cash By Market Cap	$42.9
Net Cash Growth	82.98%
Net Debt Equity	$-1.02
Tangible Book Value	$167.6M
Tangible Book Value Per Share	$0.98
WACC	9.43

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	30.14
Net Working Capital	$-3.9M
Quick ratio	29.83
Working Capital	$166.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-167.35%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	17.68%
200-day SMA	1.75
3Y total return	-14.65%
50-day SMA	1.86
50-day SMA vs 200-day SMA	50over200
5Y total return	-84.08%
All Time High	70.8
All Time High Change	-96.71%
All Time High Date	2020-12-23
All Time Low	0.79
All Time Low Change	194.94%
All Time Low Date	2023-10-10
ATR	0.14
Beta	0.94
Beta1y	1.12
Beta2y	1.65
Ch YTD	13.66
High	2.53
High52	2.53
High52 Date	2026-07-24
High52ch	-7.91%
Low	2.32
Low52	1.33
Low52 Date	2025-11-03
Low52ch	75.19%
Ma50ch	25.07%
Premarket Change Percent	3
Premarket Price	$2.4
Premarket Volume	2,874
Price vs 200-day SMA	33.07%
RSI	71.84
RSI Monthly	46.02
RSI Weekly	64.41
Sharpe ratio	0.52x
Sortino ratio	0.92
Total Return	-167.35%
Tr YTD	13.66
Tr1m	24.6%
Tr1w	10.43%
Tr3m	20.73%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	3
Analyst Price Target Top	$6.33
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.09
Operating Income	$-48.4M
Price target	$6
Price Target Change	$158
Price Target Change Top	$172

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	61,878,876%
Float Percent	36.31%
Shares Insiders	1.55%
Shares Institutions	51.16%
Shares Out	170,422,294
Shares Qo Q	39.36%
Shares Yo Y	167.35%
Short Float	31.39%
Short Ratio	23.29
Short Shares	11.4

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-54.6M
Average Volume	1,262,754x
Bv Per Share	0.98
Ch1m	24.6
Ch1w	10.43
Ch1y	17.68
Ch3m	20.73
Ch3y	-14.65
Ch5y	-84.08
Ch6m	33.91
Change	0%
Change From Open	-1.69
Close	2.33
Days Gap	1.72
Depreciation Amortization	62,970
Dollar Volume	5,029,097.6
Earnings Date	2026-08-13
Earnings Time	amc
EBIT	$-55.2M
EBITDA	$-55.2M
EPS	$-0.43
F Score	2
FCF	$-35.7M
FCF EV Yield	-15.77x
FCF Per Share	$-0.21
Financing CF	111,360,574
Fiscal Year End	December
Founded	2,008
Investing CF	-99,485,799
Ipr	-76.7
Iprfo	-96.36
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Date	2023-06-30
Last Split Type	Reverse
Last10k Filing Date	2026-03-26
Ma150	1.82
Ma150ch	28.16%
Ma20	2.07
Ma20ch	12.4%
Net CF	-23,867,881
Next Earnings Date	2026-08-13
Open	2.37
Optionable	No
Position In Range	4.76
Post Close	2.33
Postmarket Change Percent	1.72
Postmarket Price	$2.37
Pre Close	2.33
Price Date	2026-07-24
Ptbv Ratio	2.37
Relative Volume	1.71x
Share Based Comp	18,827,494
Tr6m	33.91%
Us State	Delaware
Volume	2,158,411

Inhibikase Therapeutics, Inc. (IKT)

Coverage state: Market snapshot only — no published research

Generate the first IKT analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IKT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IKT indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IKT

Frequently asked questions